VRSA-doomsday superbug or damp squib?

The Lancet Infectious Diseases

Volumn 10, Issue 12, 2010, Pages 816-818

  Gould, Ian M ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPEPTIDE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL GENE; ENTEROCOCCUS FAECALIS; HORIZONTAL GENE TRANSFER; INDIA; IRAN; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NECROTIZING FASCIITIS; NONHUMAN; OSTEOMYELITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; UNITED STATES; VANA GENE; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; HUMANS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 78649395979     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70259-0     Document Type: Letter

References (15)

1. Herriman R Rare resistant staph infection seen in Pennsylvania hospital (accessed Nov 5, 2010). http://www.examiner.com/infectious-disease-in-national/rare-resistant-staph-infection-seen-pennsylvania-hospital.
2. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008, 46:668-674.
3. Finks J, Wells E, Dyke TL, et al. Vancomycin-resistant Staphylococcus aureus, Michigan, USA, 2007. Emerging Infect Dis 2009, 15:943-945.
4. Saha B, Singh AK, Ghosh A, Bal M Identification and characterization of a vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia). J Med Microbiol 2008, 57:72-79.
5. Aligholi M, Emaneini M, Jabalameli F, Shahsavan S, Dabiri H, Sedaght H Emergence of high-level vancomycin-resistant Staphylococcus aureus in the Imam Khomeini hospital in Tehran. Med Princ Pract 2008, 17:432-434.
6. Foucault ML, Courvalin P, Grillot-Courvalin C Fitness cost of VanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009, 53:2354-2359.
7. Tenover FC Vancomycin-resistant Staphylococcus aureus: a perfect but geographically limited storm?. Clin Infect Dis 2008, 46:675-677.
8. Swenson JM, Anderson KF, Lonsway DR, et al. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus. J Clin Micro 2009, 47:2013-2017.
9. Kalil AC, Murthy MH, Hermsen ED, Neto FK, Sun J, Rupp ME Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med 2010, 38:1802-1808.
10. Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355:653-665. for the S aureus Endocarditis and Bacteremia Study Group.
11. Arhin FF, Sarmiento I, Parr TR, Moeck G Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin. J Antimicrob Chemother 2009, 64:868-870.
12. Deresinski S Counterpoint: vancomycin and Staphylococcus aureus-an antibiotic enters obsolescence. Clin Infect Dis 2007, 44:1543-1548.
13. Performance standards for antimicrobial disk susceptibility tests; approved standard-tenth addition Clinical and Laboratory Standards Institute, (accessed Nov 5, 2010). http://www.clsi.org/source/orders/free/m02-a10.pdf.
14. European Society of Clinical Microbiology and Infectious Diseases, (accessed Nov 5, 2010). http://www.escmid.org/research_projects/eu_cast/.
15. Hsu DI, Hidayat LK, Quist R, et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob. Agents 2008, 32:378-385.